Learn more about Elmiron Lawsuits. Below, we provide resources and news updates.
If you or a loved one took Elmiron and were diagnosed with a vision disorder or experienced vision loss symptoms, please contact our law firm. You may be legally entitled to compensation. Schedule a free confidential evaluation of your potential claim by calling us at (866) 575-7435.
With over 200 cases filed against Janssen Pharmaceuticals concerning vision-related problems linked to Elmiron, plaintiffs are seeing new developments towards trial, possibly in 2023. Plaintiffs allege long-term use of the bladder-pain drug caused vision impairment symptoms, and for many, a degenerative eye disorder called “pigmentary maculopathy.” The cases were consolidated into a multi-district litigation in …. Read More
Women across the country are filing lawsuits against Janssen Pharmaceuticals, manufacturer of the drug Elmiron, claiming the drug caused their vision problems such as maculopathy. Long-term use of the drug, which is prescribed to treat bladder pain, has been linked to vision problems such as blurry vision, loss of close vision, night blindness, and other …. Read More
G&E principal Sindhu Daniel was selected to serve on the Plaintiffs Steering Committee in the Elmiron Multidistrict Litigation (MDL). The leadership team includes mostly female attorneys and is a highly diverse group. Approximately 130 Elmiron lawsuits were centralized in December 2020 before The Honorable Brian R. Martinotti in New Jersey to expedite pretrial proceedings. As …. Read More
In December 2020, approximately 130 Elmiron lawsuits were consolidated into a multi-district litigation (MDL) to streamline pre-trial proceedings. On January 8, 2021, lawyers met with Judge Brian R. Martinotti, the New Jersey District Judge overseeing the litigation, via Zoom to hold a case management conference. As the litigation moves forward, the MDL aims to streamline …. Read More
Plaintiffs in the Elmiron litigation have selected a proposed group of attorneys which includes G&E director Sindhu Daniel to serve as the Plaintiff Steering Committee. The team of lawyers from all over the country is highly diverse and comprised mostly of female attorneys. The Elmiron litigation concerns a drug manufactured by Janssen Pharmaceuticals designed to …. Read More
The link between Elmiron and vision damage has come to the forefront of recent news—as well as the courtroom. Many patients experiencing vision loss symptoms are looking for answers to questions such as: does Elmiron cause macular degeneration? Our law firm is investigating vision loss claims nationwide due to Elmiron. Learn more about Elmiron, vision …. Read More
In the latest news in the Elmiron litigation, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has approved all Elmiron lawsuits to be consolidated in the District of New Jersey before Brian R. Martinotti. This tactic, called a multi-district litigation, or MDL, consolidates cases that allege similar claims to expedite pretrial proceedings and eliminate duplicative …. Read More
As patients that took Elmiron continue to file lawsuits concerning its vision-loss side-effects, a new case report indicates some alarming findings. In the report, published in Retinal Cases & Brief Reports, doctors from Emory University School of Medicine describe a woman who experienced vision problems three years after stopping Elmiron. The 44-year old developed Elmiron-induced …. Read More
Have you had prolonged exposure to Elmiron? Are you suffering from vision problems or other Elmiron long term side effects? Many individuals that took Elmiron and experienced vision problems have filed lawsuits against the manufacturer, Janssen Pharmaceuticals. These lawsuits allege that Janssen failed to warn doctors and patients about the risks of vision problems associated …. Read More
As litigation against Janssen Pharmaceuticals, manufacturer of bladder pain drug Elmiron, mounts, the FDA has approved a change in the drug’s labeling in the U.S. The label of the drug’s “Warnings” section previously did not list any risks concerning visual impairment; however, labeling must now contain “Retinal Pigmentary Changes.” These changes may manifest as pigmentary …. Read More
